Involvement of the endocannabinoid system in drug addiction.

By R. Maldonado, O. Valverde, F. Berrendero. Trends in Neurosciences, 2006

605 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Cognitive Neuroscience, Pharmacology

View Paper: https://www.semanticscholar.org/paper/cab3bbaaf85ab575ffdb8de24ae93bf45b51f5ec

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. R. Pertwee
2. George Kunos
3. Tamás F. Freund
4. I. Katona
5. R. Mechoulam
6. P. Pacher
7. S. Batkai
8. L. Parker

In Cognitive Neuroscience

1. R. Pertwee
2. L. Parker
3. Tamás F. Freund
4. R. Spanagel
5. George Kunos
6. R. Mechoulam

In Pharmacology

1. R. Pertwee
2. Tamás F. Freund
3. George Kunos
4. R. Mechoulam
5. I. Katona
6. P. Pacher
7. S. Batkai
8. L. Parker

Citations in the corpus

• Alcoholism: a systems approach from molecular physiology to addictive behavior. (2009, background): “However, endocannabinoids are also involved in the motivation to seek drugs via DA-independent mechanisms (291), and an endocannabinoid hypothesis of drug reward has been postulated as an alternative to the DA hypothesis of drug reward.”
• The endocannabinoid system and the brain. (2013, methodology): “The regulation of the primary rewarding effects of drugs of abuse may be in part controlled by endocannabinoid release in the VTA, which produces inhibition of the release of GABA, thus removing the inhibitory effect of GABA on dopaminergic neurons (Maldonado et al. 2006).”
• The Endocannabinoid System as an Emerging Target of Pharmacotherapy (2006, background): “These findings suggests that endocannabinoid activation of CB1 receptors in the mesolimbic reward pathway may be part of a “common pathway” of drug reward (reviewed in De Vries and Schoffelmeer, 2005; Maldonado et al., 2006).”
• The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin (2008, background): “…the hypothesis that D9-THC may sometimes antagonize responses to endogenously released endocanna- binoids, not least because there is evidence that such release can modulate the signs and symptoms of certain disorders and/or disease progression (reviewed in Pertwee, 2005b; Maldonado et al., 2006).”
• Endocannabinoid signaling as a synaptic circuit breaker in neurological disease (2008, background): “, whereas research in the nucleus accumbens primarily explores the role of the endocannabinoid pathway in drug addictio”